Sorry, you need to enable JavaScript to visit this website.

PROSTIN VR® (alprostadil) Boxed Warning


Apnea is experienced by about 10 to 12% of neonates with congenital heart defects treated with PROSTIN VR PEDIATRIC Sterile Solution. Apnea is most often seen in neonates weighing less than 2 kg at birth and usually appears during the first hour of drug infusion. Therefore, respiratory status should be monitored throughout treatment, and PROSTIN VR PEDIATRIC should be used where ventilatory assistance is immediately available.

What's New

No Current Announcements.


Please enter your search term(s) for PROSTIN VR®